

Signatera™

Residual disease test (MRD)

Detect relapse or progression early

A new way to get earlier, more precise information after cancer treatment



Brought to you by Natera, a global leader in genetic testing and cell-free DNA analysis

 **natera**
Conceive. Deliver. Thrive.



Molecular residual disease is the presence of small traces of cancer in the blood, such as circulating tumor DNA (ctDNA) or microscopic pieces of tumor DNA.

Why is cancer surveillance important?

Knowing if there are traces of cancer present, can help the doctor or oncologist decide:

- How the patient is responding to treatment
- If further cancer treatment needs to be considered
- Whether there are signs that the cancer has returned or progressed

The most common imaging tools used to detect the presence of cancer include computerized tomography (CT) scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, mammography, and x-ray. These imaging tools are limited in their ability to detect molecular residual disease (MRD), which are very small traces of cancer in the blood. If left untreated, residual cancer cells are highly likely to multiply and cause a recurrence.



Signatera is a new cancer-surveillance test that is personalized for each patient

Signatera is a custom-designed test that is generated based on each patient's unique set of tumor mutations.

Knowing earlier if your cancer is likely to recur or has progressed after treatment can help you have a more informed discussion with your doctor on how to continue to treat or to detect changes in your disease.

How is the Signatera test performed?



1)

Analysis to determine your unique set of tumor mutations




2)

Create a custom-design Signatera test for you



3)

Test determines presence or absence of tumor DNA



How long will it take to receive the Signatera test results?

- The first time the Signatera test is ordered, it will take 2 weeks from the date the tumor tissue and required blood samples are received for tumor tissue sequencing results to become available. Then, it will take another 2 weeks for your personalized test design and for your physician to receive the first Signatera test result.
- After the test has been designed, it will take 1 to 2 weeks after your blood sample is received by the Natera laboratory for your subsequent Signatera test results to become available to your physician.

What do the Signatera test results mean?


Your test result will either be positive or negative for the presence of tumor DNA in your blood.

If you have early-stage cancer:

A positive result means there is higher risk for your cancer returning. A negative result means that you are more likely to remain cancer-free.

If you have metastatic cancer:

Your doctor may look for changes in ctDNA levels to assess your tumor's response to treatment.





How accurate is the Signatera residual disease test?

Signatera can detect extremely small amounts of tumor DNA before cancer recurrence can be seen by traditional imaging tools such as CT scans or MRI. The Signatera test is highly sensitive and specific, meaning that if your test result is positive, there is a high likelihood that your cancer may recur without further treatment. The test's ability to correctly identify the presence of molecular residual disease (MRD), is what makes Signatera unique.



When should the Signatera test be considered?

- At initial cancer diagnosis, to establish a baseline before surgery or treatment
- After surgery, before starting chemotherapy
- During treatment, to evaluate treatment response
- After treatment, to monitor for molecular residual disease or tumor response to treatment

How much does Signatera cost?

At Natera, we understand that medical tests can be expensive and billing processes can be confusing. We welcome all insurance plans and will work with you to make the test as affordable as possible. We also have an affordable self-pay rate for those patients who do not wish to use insurance.

For questions or for financial assistance, please contact Natera's Patient Advocate Team.

Phone: **650.489.9050**


Fax: **650.412.1962**

Email: **signateracc@natera.com**



For more information about Signatera or to review published studies, visit www.natera.com/signatera

Contact Natera's Patient Advocate Team by calling **650.489.9050**



About Natera, the maker of Signatera

Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide by harnessing the power of DNA from a single blood sample to improve the management of reproductive health, cancer and organ transplants.

This test was developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. © 2019 Natera, Inc. All rights reserved. 2019_08_07_NAT-801957

201 Industrial Road, Suite 410 | San Carlos, CA 94070
www.natera.com | 1.650.489.9050 | Fax 1.650.412.1962



Signatera™
Residual disease test (MRD)